Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
US drugmaker Abbott (NYSE: ABT) has officially commissioned a new line for the production of gelatine capsules at its Veropharm plant in the Russian city of Belgorod. 4 November 2016
Biotechnology
The National Institute for Health and Care excellence (NICE) has today published draft guidance for US pharma major Eli Lilly’s (ixekizumab) for psoriasis. 1 November 2016
Pharmaceutical
Melinta Therapeutics has submitted New Drug Applications (NDAs) to the US Food and Drug Administration for approval of IV and oral Baxdela (delafloxacin) for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). 24 October 2016
Biotechnology
Celgene announced today that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral Otezla (apremilast) following a positive final appraisal determination from the National Institute for Health and Care Excellence (NICE). 20 October 2016
Pharmaceutical
Allergan has received the Marketing Authorization for Belkyra (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA). 13 October 2016
Biotechnology
New results from Phase III trials of Dupixent in inadequately controlled moderate-to-severe atopic dermatitis (AD) have been announced by French pharma major Sanofi and US biotech firm Regeneron Pharmaceuticals. 3 October 2016
Pharmaceutical
New findings from the largest global survey ever carried out involving people with psoriasis show that many do not achieve the treatment goal of clear skin or even believe it is a realistic aim. 3 October 2016
Biotechnology
Leading Indian drugmaker Sun Pharma and Spain's largest drugmaker, Almirall, have announced positive results in two Phase III trials of tildrakizumab, as a potential treatment for chronic moderate-to-severe plaque psoriasis. 3 October 2016
Pharmaceutical
Greater efficacy in moderate to severe plaque psoriasis than AbbVie’s big-selling Humira (adalimumab) was just one of the findings in data presented on guselkumab, an anti-interleukin-23 monoclonal antibody, by Janssen on Saturday. 1 October 2016
Biotechnology
In what was a busy deal-making day for Maruho, the company announced licensing agreements with two fellow Japanese drugmakers, Astellas Pharma and Chugai. 29 September 2016
Biotechnology
The US Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for dupilumab, a treatment for adults with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease. 26 September 2016
Biotechnology
Taltz (ixekizumab), a monoclonal antibody (MOA) from US pharma major Eli Lilly, and Swiss pharma giant Novartis’ Cosentyx (secukinumab), will make gains in the psoriasis market at the cost of sales of TNF-inhibitors, predicts a report based on a survey of 99 US dermatologists. 20 September 2016
Pharmaceutical
Ireland-incorporated Allergan has strengthened its dermatology pipeline with the $639 million purchase of US biotech Vitae Pharmaceuticals. 14 September 2016
Pharmaceutical
Dermira has entered into an exclusive option and license agreement with Takeda Pharmaceutical for worldwide rights for up to three early-stage, small-molecule programs as potential topical treatments for dermatologic diseases. 13 September 2016
Pharmaceutical
Almirall has announced positive data from a Phase III randomized, double-blind, vehicle-controlled study evaluating the efficacy and safety of its already marketed Actikerall (5-fluorouracil (5-FU) 0.5%/salicylic acid 10%) when applied once daily as field-directed treatment to actinic keratosis (AK) lesions. 7 September 2016
article
Canadian topical drug developer Crescita Therapeutics said today that it has acquired INTEGA Skin Sciences, a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products. 1 September 2016
Pharmaceutical
Australia-headquartered Mayne Pharma says it has acquired a portfolio of on-market dermatology foam assets from UK pharma major GlaxoSmithKline for $50.1 million. 19 August 2016
Pharmaceutical
Mallinckrodt has entered into a merger agreement with Stratatech Corp, a privately-held Wisconsin-based regenerative medicine company focused on the development of unique, proprietary skin substitute products. 11 August 2016
Pharmaceutical
Canada-based drugmaker Valeant Pharmaceuticals' share price soared by more than a quarter on Tuesday – despite missing analyst predictions in its quarterly results. 10 August 2016
Pharmaceutical
Canada’s Cardiome Pharma says that Xydalba (dalbavancin) has been approved by the European Medicines Agency for administration as a single, 30 minute, 1500mg infusion (three 500mg vials). 10 August 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze